Tiziana Life Sciences #TILS – Develops Novel Investigational Treatment For Patients Infected with COVID-19 April 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London — April 9,  2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to  treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting  development…

Continue reading